Summary
Edwards Lifesciences Corporation (EW) reported a solid third quarter for 2008, demonstrating year-over-year growth in net sales and income. Net sales increased by 16.1% to $303.6 million, driven by strong performance in Heart Valve Therapy and Critical Care segments, with notable contributions from the Edwards SAPIEN transcatheter heart valve and the FloTrac monitoring system. The company's strategic focus on core businesses is evident with the divestiture of the LifeStent product line, which contributed to a special charge but streamlined operations. Despite some market uncertainties, the company maintained a healthy gross profit margin and managed its operating expenses effectively, with research and development investments continuing to fuel future growth, particularly in transcatheter valve technologies. Financially, Edwards Lifesciences maintained a healthy liquidity position, with a significant increase in cash and cash equivalents. The company also completed the redemption of its convertible senior debentures and continued its share repurchase program, indicating confidence in its financial health and commitment to shareholder value.
Key Highlights
- 1Net sales increased by 16.1% year-over-year to $303.6 million for the third quarter of 2008.
- 2Heart Valve Therapy and Critical Care segments were key growth drivers, with sales up 20.8% and 14.3% respectively.
- 3The divestiture of the LifeStent product line was completed in January 2008, resulting in a pre-tax loss of $8.1 million.
- 4The company's R&D spending increased to support advancements in transcatheter and surgical heart valve programs.
- 5Cash and cash equivalents increased significantly, ending the quarter at $202.4 million.
- 6The company redeemed its $150.0 million convertible senior debentures in June 2008.
- 7A new stock repurchase program of up to $250.0 million was authorized, with $214.5 million remaining authorization as of September 30, 2008.